重组干扰素γ治疗系统性硬化症15例  

Treatment of 15 Cases of Systemic Sclerosis with Recombinant Interferon-gamma

作　　者：施冶青[1] 韩星海[1] 刘彧[1] 赵东宝[1] 

机构地区：[1]第二军医大学长海医院风湿免疫科,上海200433

出　　处：《医药导报》2004年第8期545-546,共2页Herald of Medicine

摘　　要：目的 :观察重组干扰素γ对系统性硬化症 (SSc)的疗效和安全性。方法 :选取SSc患者 15例 ,完成 3个月的疗程 ,每日给予重组干扰素γ 10 0万U ,im ,每周 5d。结果 :治疗 3个月在皮肤硬度积分、关节功能积分、最大齿距、血沉(ESR)、C 反应蛋白等方面差异均有极显著性 ,一氧化碳弥散率差异有显著性 ,无严重不良反应发生。结论 :重组干扰素γ对SSc有效 ,且副作用低。Objective:To survey the therapeutic effectiveness and safety rate of recombinant interferon-gamma (IFN-γ) in the treatment of systemic sclerosis(SSc). Methods:15 patients with SSc served as the subjects of the study. Each patient was given a daily I.M. injection of 1 000 000 U of recombinant IFN-γ in 5 days of a week. The course of treatment lasted 3 months. Results:After the completion of the treatment course,a striking improvement was demonstrated in skin sclerosis scores,maximal oral opening,joint function index,carbon monoxide diffusing capacity(DLco),erythrocyte sedimenation rate(ESR) and content of C-reactive protein (CRP). No serious adverse reactions were encountered. Conclusion:Recombinant INF-γ was shown to be effective in the treatment of systemic sclerosis with low incidence of adverse reactions.

关 键 词：重组干扰素r 系统性硬化症 

分 类 号：R979.5[医药卫生—药品]